Equities researchers at WBB Securities assumed coverage on shares of Cytosorbents Corp
Equities researchers at WBB Securities assumed coverage on shares of Cytosorbents Corp (OTCMKTS:CTSO) in a research report issued on Wednesday. The firm set a “speculative buy” rating and a $13.00 price target on the stock.
A number of other firms have also recently commented on CTSO. Analysts at Brean Capital set a $25.00 price target on shares of Cytosorbents Corp and gave the company a “buy” rating in a research note on Thursday, February 19th. Analysts at HC Wainright raised their price target on shares of Cytosorbents Corp from $1.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, analysts at Zacks downgraded shares of Cytosorbents Corp from an “outperform” rating to a “neutral” rating and set a $10.60 price target on the stock in a research note on Wednesday, January 7th.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 11.11 on Wednesday. Cytosorbents Corp has a 52-week low of $4.40 and a 52-week high of $12.87. The stock has a 50-day moving average of $8.56 and a 200-day moving average of $8.15. The company’s market cap is $272.3 million.
CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses. The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids.
